Wikipedia:WikiProject Chemicals/Chembox validation/VerifiedDataSandbox and Halazepam: Difference between pages
Appearance
(Difference between pages)
Content deleted Content added
Saving copy of the {{drugbox}} taken from revid 461607775 of page Halazepam for the Chem/Drugbox validation project (updated: 'DrugBank'). |
Undid revision 1231783510 by 2.101.54.127 (talk) WP:BANREVERT |
||
Line 1: | Line 1: | ||
{{Short description|Chemical compound}} |
|||
{{ambox | text = This page contains a copy of the infobox ({{tl|drugbox}}) taken from revid [{{fullurl:Halazepam|oldid=461607775}} 461607775] of page [[Halazepam]] with values updated to verified values.}} |
|||
{{Drugbox |
{{Drugbox |
||
| Watchedfields = changed |
|||
| verifiedrevid = |
| verifiedrevid = 461743655 |
||
| IUPAC_name = 7-chloro- |
| IUPAC_name = 7-chloro-5-phenyl-1-(2,2,2-trifluoroethyl)-3''H''-1,4-benzodiazepin-2-one |
||
| image = Halazepam.svg |
| image = Halazepam.svg |
||
| width = |
| width = 170 |
||
| image2 = Halazepam3d.png |
| image2 = Halazepam3d.png |
||
| width2 = 150 |
|||
<!--Clinical data--> |
<!--Clinical data--> |
||
| tradename = |
| tradename = |
||
| Drugs.com = {{drugs.com|CONS|halazepam}} |
| Drugs.com = {{drugs.com|CONS|halazepam}} |
||
| MedlinePlus = a684001 |
| MedlinePlus = a684001 |
||
| pregnancy_category = ? |
| pregnancy_category = ? |
||
| legal_BR = B1 |
|||
| legal_status = [[Schedule IV controlled substance|Schedule IV]] (US) |
|||
| legal_BR_comment = <ref>{{Cite web |author=Anvisa |author-link=Brazilian Health Regulatory Agency |date=2023-03-31 |title=RDC Nº 784 - Listas de Substâncias Entorpecentes, Psicotrópicas, Precursoras e Outras sob Controle Especial |trans-title=Collegiate Board Resolution No. 784 - Lists of Narcotic, Psychotropic, Precursor, and Other Substances under Special Control|url=https://www.in.gov.br/en/web/dou/-/resolucao-rdc-n-784-de-31-de-marco-de-2023-474904992 |url-status=live |archive-url=https://web.archive.org/web/20230803143925/https://www.in.gov.br/en/web/dou/-/resolucao-rdc-n-784-de-31-de-marco-de-2023-474904992 |archive-date=2023-08-03 |access-date=2023-08-16 |publisher=[[Diário Oficial da União]] |language=pt-BR |publication-date=2023-04-04}}</ref> |
|||
| legal_CA = Schedule IV |
|||
| legal_DE = Rx-only/Anlage III |
|||
| legal_US = Schedule IV |
|||
| routes_of_administration = Oral |
| routes_of_administration = Oral |
||
<!--Pharmacokinetic data--> |
<!--Pharmacokinetic data--> |
||
| bioavailability = |
| bioavailability = |
||
| metabolism = [[Liver|Hepatic]] |
| metabolism = [[Liver|Hepatic]] |
||
| elimination_half-life = |
| elimination_half-life = 14 hours (halazepam), 50–100 hours (metabolites). |
||
| excretion = [[Kidney|Renal]] |
| excretion = [[Kidney|Renal]] |
||
<!--Identifiers--> |
<!--Identifiers--> |
||
| IUPHAR_ligand = 7195 |
|||
| CASNo_Ref = {{cascite|correct|CAS}} |
|||
| CAS_number_Ref = {{cascite|correct|??}} |
| CAS_number_Ref = {{cascite|correct|??}} |
||
| CAS_number = 23092-17-3 |
| CAS_number = 23092-17-3 |
||
Line 40: | Line 46: | ||
<!--Chemical data--> |
<!--Chemical data--> |
||
| C=17 | H=12 | Cl=1 | F=3 | N=2 | O=1 |
| C=17 | H=12 | Cl=1 | F=3 | N=2 | O=1 |
||
⚫ | |||
| molecular_weight = 352.7 |
|||
⚫ | |||
| InChI = 1/C17H12ClF3N2O/c18-12-6-7-14-13(8-12)16(11-4-2-1-3-5-11)22-9-15(24)23(14)10-17(19,20)21/h1-8H,9-10H2 |
|||
| InChIKey = WYCLKVQLVUQKNZ-UHFFFAOYAZ |
|||
| StdInChI_Ref = {{stdinchicite|correct|chemspider}} |
| StdInChI_Ref = {{stdinchicite|correct|chemspider}} |
||
| StdInChI = 1S/C17H12ClF3N2O/c18-12-6-7-14-13(8-12)16(11-4-2-1-3-5-11)22-9-15(24)23(14)10-17(19,20)21/h1-8H,9-10H2 |
| StdInChI = 1S/C17H12ClF3N2O/c18-12-6-7-14-13(8-12)16(11-4-2-1-3-5-11)22-9-15(24)23(14)10-17(19,20)21/h1-8H,9-10H2 |
||
| StdInChIKey_Ref = {{stdinchicite|correct|chemspider}} |
| StdInChIKey_Ref = {{stdinchicite|correct|chemspider}} |
||
| StdInChIKey = WYCLKVQLVUQKNZ-UHFFFAOYSA-N |
| StdInChIKey = WYCLKVQLVUQKNZ-UHFFFAOYSA-N |
||
| synonyms = <small>9-chloro- |
| synonyms = <small>9-chloro-6-phenyl-2-(2,2,2-trifluoroethyl)-2,5-diazabicyclo[5.4.0]undeca-5,8,10,12-tetraen-3-one</small> |
||
}} |
}} |
||
'''Halazepam''' is a [[benzodiazepine]] derivative that was marketed under the brand names '''Paxipam''' in the United States,<ref name=DrugsH /> '''Alapryl''' in Spain,<ref name=DrugsA>{{cite web|title=Alapryl|url=https://www.drugs.com/international/alapryl.html|publisher=Drugs.com|access-date=December 11, 2014}}</ref> and '''Pacinone''' in Portugal.<ref name=DrugsP>{{cite web|title=Pacinone|url=https://www.drugs.com/international/pacinone.html|publisher=Drugs.com|access-date=December 11, 2014}}</ref> |
|||
==Medical uses== |
|||
Halazepam was used for the treatment of [[anxiety]].<ref name=DrugsH /> |
|||
==Adverse effects== |
|||
Adverse effects include drowsiness, confusion, dizziness, and sedation. Gastrointestinal side effects have also been reported including dry mouth and nausea.<ref name=DrugsH /> |
|||
==Pharmacokinetics and pharmacodynamics== |
|||
Pharmacokinetics and pharmacodynamics were listed in ''Current Psychotherapeutic Drugs'' published on June 15, 1998 as follows:<ref>{{cite book| veditors = Quitkin FM, etal | vauthors = Sellers EM | chapter = Antianxiety agents: benzodiazepine derivatives |title = Current Psychotherapeutic Drugs |date=1998|publisher=American Psychiatric Press|location=Washington|isbn=978-0-88048-994-2 |page=166|edition=2nd}}</ref> |
|||
{| class="wikitable" |
|||
|- |
|||
| Onset of action || Intermediate to slow |
|||
|- |
|||
| Plasma half life || 14 hr for parent drug and 30-100 hr for its metabolite |
|||
|- |
|||
| Peak plasma levels || 1-3 hr for parent drug and 3-6 hf for its metabolite |
|||
|- |
|||
| Metabolism || Metabolized into desmethyldiazepam and 3-hydroxyhalazepam (in the liver) |
|||
|- |
|||
| Excretion || Excreted through kidneys |
|||
|- |
|||
| Protein binding|| 98% bound to plasma protein |
|||
|} |
|||
==Regulatory Information== |
|||
Halazepam is classified as a [[Controlled Substances Act#Schedule IV controlled substances|schedule 4]] [[controlled substance]] with a corresponding code 2762 by the [[Drug Enforcement Administration]] (DEA).<ref name=DEA>{{cite web|title=SCHEDULES OF CONTROLLED SUBSTANCES|url=http://www.gpo.gov/fdsys/pkg/CFR-2012-title21-vol9/xml/CFR-2012-title21-vol9-part1308.xml|publisher=Code of Federal Regulations|access-date=December 12, 2014|pages=§ 1308.14 Schedule IV|date=2012-04-01}}</ref> |
|||
==Commercial production== |
|||
Halazepam was invented by Schlesinger Walter in the U.S. It was marketed as an anti-anxiety agent in 1981. However, Halazepam is not commercially available in the United States because it was withdrawn by its manufacturer for poor sales.<ref name=DrugsH>{{cite web|title=halazepam|url=https://www.drugs.com/mtm/halazepam.html|publisher=Drugs.com|access-date=December 11, 2014}}</ref> |
|||
==See also== |
|||
*[[Benzodiazepine]]s |
|||
*[[Nordazepam]] |
|||
*[[Diazepam]] |
|||
*[[Chlordiazepoxide]] |
|||
*[[Quazepam]], [[fletazepam]], [[triflubazam]] — benzodiazepines with [[trifluoromethyl group]] attached |
|||
==References== |
|||
{{Reflist}} |
|||
==External links== |
|||
* [http://www.inchem.org/documents/pims/pharm/pim160.htm Inchem - Halazepam] |
|||
{{Benzodiazepines}} |
|||
{{Anxiolytics}} |
|||
{{GABAAR PAMs}} |
|||
[[Category:Withdrawn drugs]] |
|||
[[Category:Benzodiazepines]] |
|||
[[Category:Chloroarenes]] |
|||
[[Category:Lactams]] |
|||
[[Category:Trifluoromethyl compounds]] |
|||
{{sedative-stub}} |